Zentalis Pharmaceuticals, Inc. (ZNTL) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Join SI Premium – FREE
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q2 EPS of ($0.59), $0.11 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deluxe Corp. (DLX) Tops Q3 EPS by 11c; offers guidance
- Ingevity (NGVT) Tops Q3 EPS by 7c, Beats on Revenue; Offers FY26 EPS Guidance
- Centrus Energy (LEU) Misses Q3 EPS by 48c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
